相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Re: Phase II Trial of Cabozantinib Plus Nivolumab in Patients with Non-clear-cell Renal Cell Carcinoma and Genomic Correlates
Yunze Xu et al.
EUROPEAN UROLOGY (2022)
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates
Chung-Han Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Complete response of hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated renal cell carcinoma to nivolumab and ipilimumab combination immunotherapy by: a case report
Yasuhiro Iribe et al.
FAMILIAL CANCER (2021)
Integrated Molecular Characterization of Fumarate Hydratase-deficient Renal Cell Carcinoma
Guangxi Sun et al.
CLINICAL CANCER RESEARCH (2021)
Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma
Jack P. Gleeson et al.
CLINICAL CANCER RESEARCH (2021)
Response to systemic therapy in fumarate hydratase-deficient renal cell carcinoma
Lucia Carril-Ajuria et al.
EUROPEAN JOURNAL OF CANCER (2021)
A Clinicopathologic and Molecular Analysis of Fumarate Hydratase-deficient Renal Cell Carcinoma in 32 Patients
Hubert D. Lau et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2020)
Estimation of the carrier frequency of fumarate hydratase alterations and implications for kidney cancer risk in hereditary leiomyomatosis and renal cancer
Brian Shuch et al.
CANCER (2020)
Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer.
Ramaprasad Srinivasan et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The preliminary outcome of the combination of immunotherapy and targeted therapy after recurrence and metastasis for hereditary leiomyomatosis and renal cell cancer-a case report
Dechno Feng et al.
TRANSLATIONAL ANDROLOGY AND UROLOGY (2020)
Kidney Cancer, Version 1.2021 Featured Updates to the NCCN Guidelines
Robert J. Motzer et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Fumarate hydratase-deficient renal cell carcinoma: A clinicopathological study of seven cases including hereditary and sporadic forms
Naoto Kuroda et al.
ANNALS OF DIAGNOSTIC PATHOLOGY (2020)
Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients
Yeonjoo Choi et al.
CANCER RESEARCH AND TREATMENT (2019)
Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures
Inkeun Park et al.
BMC UROLOGY (2019)
Re: Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling
Yunze Xu et al.
EUROPEAN UROLOGY (2018)
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
Michael B. Atkins et al.
LANCET ONCOLOGY (2018)
Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair
Parker L. Sulkowski et al.
NATURE GENETICS (2018)
Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome (HLRCC) A Contemporary Review and Practical Discussion of the Differential Diagnosis for HLRCC-Associated Renal Cell Carcinoma
Stephanie L. Skala et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2018)
A distinctive, low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma, morphologically reminiscent of succinate dehydrogenase-deficient renal cell carcinoma
Steven C. Smith et al.
HISTOPATHOLOGY (2017)
Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents
Sang Hyun Hwang et al.
CLINICAL NUCLEAR MEDICINE (2017)
Fumarate Hydratase-deficient Renal Cell Carcinoma Is Strongly Correlated With Fumarate Hydratase Mutation and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome
Kiril Trpkov et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2016)
Radical nephrectomy and regional lymph node dissection for locally advanced type 2 papillary renal cell carcinoma in an at-risk individual from a family with hereditary leiomyomatosis and renal cell cancer: a case report
Takao Kamai et al.
BMC CANCER (2016)
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours
Holger Moch et al.
EUROPEAN UROLOGY (2016)
Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets
Ying-Bei Chen et al.
NATURE COMMUNICATIONS (2016)
Preoperative Evaluation of Renal Cell Carcinoma by Using 18F-FDG PET/CT
Miwako Takahashi et al.
CLINICAL NUCLEAR MEDICINE (2015)
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
Ronald Boellaard et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment
Fred H. Menko et al.
FAMILIAL CANCER (2014)
The Glycolytic Shift in Fumarate-Hydratase-Deficient Kidney Cancer Lowers AMPK Levels, Increases Anabolic Propensities and Lowers Cellular Iron Levels
Wing-Hang Tong et al.
CANCER CELL (2011)
Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma
Betty Gardie et al.
JOURNAL OF MEDICAL GENETICS (2011)
Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status
Chiara Bardella et al.
JOURNAL OF PATHOLOGY (2011)
Exploring a glycolytic inhibitor for the treatment of an FH-deficient type-2 papillary RCC
Toshinari Yamasaki et al.
NATURE REVIEWS UROLOGY (2011)
Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer
IPM Tomlinson et al.
NATURE GENETICS (2002)
分享论文
